EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HIV-1 Proviral Genome Engineering with CRISPR-Cas9 for Mechanistic Studies

Usman Hyder iD, Ashutosh Shukla, Ashwini Challa, Iván D'Orso iD

Viruses · 2024

DOI: 10.3390/v16020287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Usman Hyder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HIV-1 latency remains a barrier to a functional cure because of the ability of virtually silent yet inducible proviruses within reservoir cells to transcriptionally reactivate upon cell stimulation. HIV-1 reactivation occurs through the sequential action of host transcription factors (TFs) during the “host phase” and the viral TF Tat during the “viral phase”, which together facilitate the positive feedback loop required for exponential transcription, replication, and pathogenesis. The sequential action of these TFs poses a challenge to precisely delineate the contributions of the host and viral phases of the transcriptional program to guide future mechanistic and therapeutic studies. To address this limitation, we devised a genome engineering approach to mutate tat and create a genetically matched pair of Jurkat T cell clones harboring HIV-1 at the same integration site with and without Tat expression. By comparing the transcriptional profile of both clones, the transition point between the host and viral phases was defined, providing a system that enables the temporal mechanistic interrogation of HIV-1 transcription prior to and after Tat synthesis. Importantly, this CRISPR method is broadly applicable to knockout individual viral proteins or genomic regulatory elements to delineate their contributions to various aspects of the viral life cycle and ultimately may facilitate therapeutic approaches in our race towards achieving a functional cure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHumansProvirusesCRISPR-Cas SystemsVirus Latency

Stichwörter der Autor:innen

CRISPRCas9HIV-1Tatgenome engineeringtranscriptionviruses

Autor:innen und Institutionen

  • Department of Microbiology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Usman Hyder, Iván D'Orso

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • NIAID
  • NCI
  • UTSW Simmons Comprehensive Cancer Center

Zitieren

APA

Hyder, U., Shukla, A., Challa, A., & D'Orso, I. (2024). HIV-1 Proviral Genome Engineering with CRISPR-Cas9 for Mechanistic Studies. Viruses. https://doi.org/10.3390/v16020287

Vancouver

Hyder U, Shukla A, Challa A, D'Orso I. HIV-1 Proviral Genome Engineering with CRISPR-Cas9 for Mechanistic Studies. Viruses. 2024. doi:10.3390/v16020287

BibTeX
@article{Hyder2024,
  author = {Hyder, Usman and Shukla, Ashutosh and Challa, Ashwini and D'Orso, Iván},
  title = {HIV-1 Proviral Genome Engineering with CRISPR-Cas9 for Mechanistic Studies},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16020287}
}
Kostenlos starten →